<DOC>
	<DOCNO>NCT01352442</DOCNO>
	<brief_summary>The purpose study determine AcuFocus Corneal Inlay ACI 7000PDT provide effective method correction presbyopia patient normal distance vision need correction glass contact lenses see clearly near .</brief_summary>
	<brief_title>Safety Effectiveness AcuFocus Corneal Inlay ACI7000PDT Presbyopes</brief_title>
	<detailed_description>The design mechanism action AcuFocus™ Corneal Inlay ( ACI 7000PDT ) base well-established concept small-aperture optic . In camera , depth focus control reduce aperture light enters ; small aperture , great depth focus . This concept also apply human eye . In eye emmetropic presbyope , natural lens fully accommodate focus light ray near object onto single point retina . Thus , point object image blur circle retina , image extend object degrade well . If opaque disc small aperture center place front eye , peripheral ray obscure central ray pas unaffected . Since peripheral ray enter eye large angle , create large blur circle retinal image plane . Eliminating peripheral ray reduces size blur circle , improve image resolution . When inlay implant one eye , increase depth focus provide near intermediate visual acuity minimal effect distance acuity . Under binocular condition , effect inlay eye range vision distance near combine uncorrected vision fellow presbyopic eye , essentially good distance acuity reduce near acuity , similar contact lens modality know `` modified monovision . '' The ACI expect provide presbyopic patient improvement near intermediate vision .</detailed_description>
	<mesh_term>Presbyopia</mesh_term>
	<criteria>1 . Subjects must sign give copy write Informed Consent form . 2 . Subjects must emmetropes need magnitude +1.00D +2.50D read add . 3 . Subjects must distance correct near visual acuity worse 20/40 good 20/100 eye implant . 4 . Subjects must distance visual acuity correctable least 20/20 eye . 5 . Subjects must preoperative spherical equivalent plano define Plano 0.75D 0.75D refractive cylinder determine cycloplegic refraction eye implant . 6 . Subjects must stable refraction twelve month prior ACI implantation : i.e . MRSE within 0.50D prior twelve month determine subject history . 7 . Subjects soft contact lens wearer must discontinue contact lens least one week prior ACI preoperative examination . 8 . Subjects must minimum central corneal thickness ≥ 500 micron eye implant . 9 . Subjects must corneal power ≥ 41.00D ≤ 47.00D meridian eye implant . 10 . Subjects must ≥ 45 year ≤ 60 year age time subject eligibility visit . 11 . Subjects must endothelial cell count ≥ 2000 cells/mm2 eye implant . 12 . Subjects must willing able return schedule followup examination 12 month surgery . 13 . Subjects must demonstrate tolerance monovision blur eye implant determine loose lens blur tolerance monovision contact lens trial . 1 . Subjects difference &gt; 1.00D spherical equivalent manifest refraction spherical equivalent cycloplegic refraction . 2 . Subjects anterior segment pathology , include cataract , eye implant . 3 . Subjects residual , recurrent , active ocular uncontrolled eyelid disease , corneal abnormality ( include endothelial dystrophy , guttata , recurrent corneal erosion , etc . ) eye implant . 4 . Subjects ophthalmoscopic topographic sign keratoconus ( keratoconus suspect ) keratoectasia eye implant . 5 . Subjects dry eye determine objective testing ; anesthetize Schirmer 's test result &lt; 10 mm tear breakup time ( TBUT ) less 10 second exclude . 6 . Subjects take chronic systemic medication know exacerbate induce moderate severe dry eye far measure TBUT Schirmers decrease borderline per Exclusion Criterion # 5 . Subjects take follow class medication evaluate : antidepressant , antihistamine , betablockers , phenothiazine , atropine atropine derivative , oral contraceptive , anxiolytic , diuretic , anticholinergic , antiarrhythmic . 7 . Subjects distort unclear corneal mire topography map eye implant . 8 . Subjects macular degeneration , retinal detachment , fundus pathology would prevent acceptable visual outcome eye implant . 9 . Subjects worn RGP PMMA contact lenses within last 6 month . 10 . Subjects undergone previous intraocular corneal surgery , include PRK , LASIK , CK , LASEK , cataract surgery eye implant . 11 . Subjects history herpes zoster herpes simplex keratitis . 12 . Subjects history steroidresponsive rise intraocular pressure , preoperative IOP &gt; 21 mmHg , glaucoma , ocular hypertension , glaucoma suspect . 13 . Subjects abnormal threshold visual field . 14 . Subjects history diagnose diabetes , diagnose autoimmune disease , connective tissue disease , clinically significant atopic syndrome . 15 . Subjects chronic systemic corticosteroid immunosuppressive therapy may affect wound healing , immunocompromised subject . 16 . Subjects use ophthalmic medication ( ) artificial tear treatment ocular pathology include ocular allergy . 17 . Subjects use systemic medication significant ocular side effect . 18 . Subjects pregnant , lactating , childbearing potential practicing medically approve method birth control . 19 . Subjects know sensitivity plan study concomitant medication . 20 . Subjects participate ophthalmic drug device clinical trial time clinical investigation .</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Presbyopia</keyword>
	<keyword>Accommodation</keyword>
	<keyword>Near visual acuity</keyword>
	<keyword>LASIK</keyword>
</DOC>